Three biologics to be released as alternatives to statins
Three biologics that can treat chronic acute coronary syndrome (ACS) will be released in the next decade as alternatives to statins.
Amgen’s evolocumab, Sanofi and Regeneron’s alirocumab and Pfizer’s bococizumab are expected to be approved and launched between 2014 and 2023, according to a report by research and consulting firm GlobalData.
It reports the monoclonal antibodies, all PCSK9 inhibitors, are safe treatments and major clinical trials have demonstrated significant reductions of LDL-C.
GlobalData analyst Eric Dimise says the biologics are likely to be prescribed long-term